Citation: | GAO Dai, ZHANG Zhuoli. Concept and development of glucocorticoid application in systemic lupus erythematosus under treat-to-target strategy[J]. Chinese Journal of General Practice, 2023, 21(8): 1279-1283. doi: 10.16766/j.cnki.issn.1674-4152.003102 |
[1] |
谢长好, 李志军. 系统性红斑狼疮的诊断与治疗[J]. 中华全科医学, 2020, 18(4): 527-528. http://www.zhqkyx.net/article/id/240c4592-9f47-4c70-a324-2bf8221505c8
XIE C H, LI Z J. Diagnosis and treatment of systemic lupus erythematosus[J]. Chinese Journal of General Practice, 2020, 18(4): 527-528. http://www.zhqkyx.net/article/id/240c4592-9f47-4c70-a324-2bf8221505c8
|
[2] |
TIAN J, ZHANG D, YAO X, et al. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study[J]. Ann Rheum Dis, 2023, 82(3): 351-356. doi: 10.1136/ard-2022-223035
|
[3] |
DUARTE-GARCIA A, HOCAOGLU M, VALENZUELA-ALMADA M, et al. Rising incidence and prevalence of systemic lupus erythematosus: a population-based study over four decades[J]. Ann Rheum Dis, 2022. DOI: 10.1136/annrheumdis-2022-222276.
|
[4] |
TSELIOS K, GLADMAN D D, TOUMA Z, et al. Monophasic disease course in systemic lupus erythematosus[J]. J Rheumatol, 2018, 45(8): 1131-1135. doi: 10.3899/jrheum.171319
|
[5] |
STREHL C, EHLERS L, GABER T, et al. Glucocorticoids-all-rounders tackling the versatile players of the immune system[J]. Front Immunol, 2019, 10: 1744. doi: 10.3389/fimmu.2019.01744
|
[6] |
HARDY R S, RAZA K, COOPER M S. Therapeutic glucocorticoids: mechanisms of actions in rheumatic diseases[J]. Nat Rev Rheumatol, 2020, 16(3): 133-144. doi: 10.1038/s41584-020-0371-y
|
[7] |
INGAWALE D K, MANDLIK S K. New insights into the novel anti-inflammatory mode of action of glucocorticoids[J]. Immunopharmacol Immunotoxicol, 2020, 42(2): 59-73. doi: 10.1080/08923973.2020.1728765
|
[8] |
PORTA S, DANZA A, ARIAS SAAVEDRA M, et al. Glucocorticoids in systemic lupus erythematosus. Ten questions and some issues[J]. J Clin Med, 2020, 9(9): 2709. doi: 10.3390/jcm9092709
|
[9] |
RUIZ-IRASTORZA G, BERTSIAS G. Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs[J]. Rheumatology (Oxford), 2020, 59 (Suppl5): v69-v81.
|
[10] |
GAO H, WANG Q, YU X, et al. Molecular mechanisms of glucocorticoid resistance in systemic lupus erythematosus: a review[J]. Life Sci, 2018, 209: 383-387. doi: 10.1016/j.lfs.2018.08.038
|
[11] |
STREHL C, BIJLSMA J W, DE WIT M, et al. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force[J]. Ann Rheum Dis, 2016, 75(6): 952-957. doi: 10.1136/annrheumdis-2015-208916
|
[12] |
BULTINK I E M, DE VRIES F, VAN VOLLENHOVEN R F, et al. Mortality, causes of death and influence of medication use in patients with systemic lupus erythematosus vs matched controls[J]. Rheumatology (Oxford), 2021, 60(1): 207-216. doi: 10.1093/rheumatology/keaa267
|
[13] |
AKIYAMA S, HAMDEH S, MICIC D, et al. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis[J]. Annals of the Rheumatic Diseases, 2021, 80(3): 384-391. doi: 10.1136/annrheumdis-2020-218946
|
[14] |
LIU X, ZHANG L, ZHANG F, et al. Prevalence and risk factors of active tuberculosis in patients with rheumatic diseases: a multi-center, cross-sectional study in China[J]. Emerg Microbes Infect, 2021, 10(1): 2303-2312. doi: 10.1080/22221751.2021.2004864
|
[15] |
ABE K, ISHIKAWA Y, KITA Y, et al. Association of low-dose glucocorticoid use and infection occurrence in systemic lupus erythematosus patients: a prospective cohort study[J]. Arthritis Res Ther, 2022, 24(1): 179. doi: 10.1186/s13075-022-02869-9
|
[16] |
SHIMADA H, WAKIYA R, KANENISHI K, et al. Preterm birth is strongly affected by the glucocorticoid dose during pregnancy in women complicated by systemic lupus erythematosus[J]. Arthritis Res Ther, 2022, 24(1): 10. doi: 10.1186/s13075-021-02699-1
|
[17] |
UGARTE-GIL M F, MAK A, LEONG J, et al. Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies[J]. Lupus Sci Med, 2021, 8(1): e000590. DOI: 10.1136/lupus-2021-000590.
|
[18] |
DAVIDSON J E, FU Q, RAO S, et al. Quantifying the burden of steroid-related damage in SLE in the Hopkins Lupus Cohort[J]. Lupus Sci Med, 2018, 5(1): e000237. DOI: 10.1136/lupus-2017-000237.
|
[19] |
APOSTOLOPOULOS D, KANDANE-RATHNAYAKE R, LOUTHRENOO W, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study[J]. The Lancet Rheumatology, 2020, 2(1): e24-e30. doi: 10.1016/S2665-9913(19)30105-5
|
[20] |
DANZA A, GRANA D, SOTO E, et al. Prednisone and long-term damage in systemic lupus erythematosus: Which is the threshold dose? A pilot study[J]. Lupus, 2022, 31(7): 880-884. doi: 10.1177/09612033221093485
|
[21] |
LITTLE J, PARKER B, LUNT M, et al. Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort[J]. Rheumatology (Oxford), 2018, 57(4): 677-687. doi: 10.1093/rheumatology/kex444
|
[22] |
GAO D, HAO Y, MU L, et al. Frequencies and predictors of the Lupus Low Disease Activity State and remission in treatment-naive patients with systemic lupus erythematosus[J]. Rheumatology (Oxford), 2020, 59(11): 3400-3407. doi: 10.1093/rheumatology/keaa120
|
[23] |
PARRA SANCHEZ A R, VOSKUYL A E, VAN VOLLENHOVEN R F. Treat-to-target in systemic lupus erythematosus: advancing towards its implementation[J]. Nat Rev Rheumatol, 2022, 18(3): 146-157. doi: 10.1038/s41584-021-00739-3
|
[24] |
ZEN M, GATTO M, DORIA A. Defining the targets in SLE management: insights and unmet gaps[J]. Ann Rheum Dis, 2022, 81(11): 1483-1485. doi: 10.1136/ard-2022-222991
|
[25] |
SAMOES B, ZEN M, ABELHA-ALEIXO J, et al. Ca. veats and pitfalls in defining low disease activity in systemic lupus erythematosus[J]. Autoimmun Rev, 2022, 21(10): 103165. DOI: 10.1016/j.autrev.2022.103165.
|
[26] |
FRANKLYN K, LAU C S, NAVARRA S V, et al. Definition and initial validation of a lupus low disease activity state (LLDAS)[J]. Ann Rheum Dis, 2016, 75(9): 1615-1621. doi: 10.1136/annrheumdis-2015-207726
|
[27] |
VAN VOLLENHOVEN R F, BERTSIAS G, DORIA A, et al. 2021 DORIS definition of remission in SLE: final recommendations from an international task force[J]. Lupus Sci Med, 2021, 8(1): e000538. DOI: 10.1136/lupus-2021-000538.
|
[28] |
BANDHAN I H, ISLAM M N, AHMAD H I, et al. Outcome of low-dose prednisolone use for the induction of remission in lupus nephritis patients[J]. Int J Rheum Dis, 2022, 25(2): 121-130. doi: 10.1111/1756-185X.14265
|
[29] |
TSELIOS K, GLADMAN D D, SU J, et al. Gradual glucocorticosteroid withdrawal is safe in clinically quiescent systemic lupus erythematosus[J]. ACR Open Rheumatol, 2021, 3(8): 550-557. doi: 10.1002/acr2.11267
|
[30] |
MIYAWAKI Y, SHIMIZU S, OGAWA Y, et al. Association of glucocorticoid doses and emotional health in lupus low disease activity state (LLDAS): a cross-sectional study[J]. Arthritis Res Ther, 2021, 23(1): 79. doi: 10.1186/s13075-021-02466-2
|
[31] |
RUIZ-IRASTORZA G. Can we effectively treat lupus and reduce the side-effects of glucocorticoids?[J]. The Lancet Rheumatology, 2020, 2(1): e3-e5. doi: 10.1016/S2665-9913(19)30132-8
|
[32] |
HOUSSIAU F A. Time to change the primary outcome of lupus trials[J]. Ann Rheum Dis, 2019, 78(5): 581-582. doi: 10.1136/annrheumdis-2018-213788
|
[33] |
FANOURIAKIS A, KOSTOPOULOU M, ALUNNO A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus[J]. Ann Rheum Dis, 2019, 78(6): 736-745. doi: 10.1136/annrheumdis-2019-215089
|
[34] |
FANOURIAKIS A, KOSTOPOULOU M, CHEEMA K, et al. 2019 update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis[J]. Ann Rheum Dis, 2020, 79(6): 713-723. doi: 10.1136/annrheumdis-2020-216924
|
[35] |
MATHIAN A, PHA M, HAROCHE J, et al. Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial[J]. Ann Rheum Dis, 2020, 79(3): 339-346. doi: 10.1136/annrheumdis-2019-216303
|
[36] |
JI L, GAO D, HAO Y, et al. Low-dose glucocorticoids withdrawn in systemic lupus erythematosus: a desirable and attainable goal[J]. Rheumatology (Oxford), 2022, 62(1): 181-189. DOI: 10.1093/rheumatology/keac225.
|
[37] |
TANI C, ELEFANTE E, SIGNORINI V, et al. Glucocorticoid withdrawal in systemic lupus erythematosus: are remission and low disease activity reliable starting points for stopping treatment? A real-life experience[J]. RMD Open, 2019, 5(2): e000916. DOI: 10.1136/rmdopen-2019-000916.
|
[38] |
GOSWAMI R P, SIT H, GHOSH P, et al. Steroid-free remission in lupus: myth or reality; an observational study from a tertiary referral centre[J]. Clin Rheumatol, 2019, 38(4): 1089-1097. doi: 10.1007/s10067-018-4377-7
|
[39] |
FASANO S, COSCIA M A, PIERRO L, et al. Which patients with systemic lupus erythematosus in remission can withdraw low dose steroids? Results from a single inception cohort study[J]. Lupus, 2021, 30(6): 991-997. doi: 10.1177/09612033211002269
|
[40] |
OON S, HUQ M, GODFREY T, et al. Systematic review, and meta-analysis of steroid-sparing effect, of biologic agents in randomized, placebo-controlled phase 3 trials for systemic lupus erythematosus[J]. Semin Arthritis Rheum, 2018, 48(2): 221-239. doi: 10.1016/j.semarthrit.2018.01.001
|
[41] |
MOK C C, HAMIJOYO L, KASITANON N, et al. The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosus[J]. The Lancet Rheumatology, 2021, 3(7): e517-e531. doi: 10.1016/S2665-9913(21)00009-6
|
[42] |
FANOURIAKIS A, TZIOLOS N, BERTSIAS G, et al. Update omicronn the diagnosis and management of systemic lupus erythematosus[J]. Ann Rheum Dis, 2021, 80(1): 14-25. doi: 10.1136/annrheumdis-2020-218272
|
[43] |
RUIZ-IRASTORZA G. Prednisone in systemic lupus erythematosus: taper quickly, withdraw slowly[J]. Rheumatology (Oxford), 2021, 60(12): 5489-5490. doi: 10.1093/rheumatology/keab347
|
[44] |
ZHANG T, LIANG Y, ZHANG J. Natural and synthetic compounds as dissociated agonists of glucocorticoid receptor[J]. Pharmacol Res, 2020, 156: 104802. DOI: 10.1016/j.phrs.2020.104802.
|
[45] |
BUTTGEREIT F, STRAND V, LEE E B, et al. Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase Ⅱb study[J]. RMD Open, 2019, 5(1): e000889. DOI: 10.1136/rmdopen-2018-000889.
|